HeartBeam Inc. (NASDAQ: BEAT), a medical technology company focused on cardiac care innovation, announced it will host a conference call on May 13, 2026, at 4:30 p.m. Eastern time to discuss its first-quarter financial results for the period ended March 31, 2026. The call will also provide updates on key growth initiatives, including the limited commercial launch for arrhythmia assessment, extended-wear patch development, heart attack detection, and artificial intelligence programs.
The company’s 3D ECG technology, which received FDA clearance for arrhythmia assessment in December 2024 and for 12-lead ECG synthesis software in December 2025, is designed to enable cable-free, portable ECG monitoring. This platform allows for the collection of ECG signals from three non-coplanar directions and synthesizes them into a standard 12-lead ECG, potentially enabling physicians to monitor cardiac health trends and detect acute conditions outside of medical facilities. For more details on the cleared indications for use, visit HeartBeam Indications.
The upcoming earnings call is expected to shed light on the company’s commercial traction and progress in bringing its technology to market. HeartBeam’s limited commercial launch for arrhythmia assessment represents a key milestone in its strategy to address the growing need for remote cardiac monitoring. The extended-wear patch development aims to provide continuous monitoring over longer periods, while the heart attack detection and AI programs are focused on leveraging advanced analytics to improve diagnostic accuracy and patient outcomes.
HeartBeam holds over 20 issued patents related to its technology, underscoring its commitment to innovation in cardiac care. The company’s platform is designed to deliver actionable heart intelligence, allowing physicians to identify trends and acute conditions and direct patients to appropriate care, potentially redefining cardiac health management. For the latest news and updates on HeartBeam, visit NNW.fm/BEAT.
Investors and stakeholders can access the full press release and additional information on the company’s newsroom at IBN.fm/yN939. The conference call will provide a comprehensive overview of the company’s financial performance, strategic direction, and upcoming milestones. As HeartBeam continues to advance its 3D ECG technology, the outcomes of these initiatives could have significant implications for the remote monitoring and early detection of cardiac conditions, potentially improving patient care and reducing healthcare costs.
